Patients from 22+ countriesPlan your visit →
lutetium-therapy
Access & Cost · 25 Jul 2026

Will Your Insurance Pay for Lu-177 PSMA Therapy

Insurance can cover Pluvicto for eligible mCRPC patients, but prior authorization is almost always required and denials are common. Here is how to build a strong appeal, what Medicare covers, and what financial assistance programs exist if coverage falls short.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 25 Jul 2026
Will Your Insurance Pay for Lu-177 PSMA Therapy

This article is about Lu-177 PSMA therapy for men with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). If that describes your situation, you may already be asking your care team about Pluvicto - the brand name for lutetium Lu 177 vipivotide tetraxetan. The next question is often practical: will your insurance pay for it, and what happens if it says no?

The direct answer is that US insurance plans, including Medicare, do cover Pluvicto for patients who meet FDA-approved criteria. Almost every plan requires prior authorization before the first cycle. Denials happen, but doctors and patients overturn a significant share of initial denials on appeal when they present a solid clinical case. Understanding how the system works helps you.

What the FDA Approval Means for Insurance

The FDA first approved Pluvicto in March 2022 for adults with PSMA-positive mCRPC who had received at least one androgen receptor pathway inhibitor (ARPI - a hormone therapy) and at least one taxane-based chemotherapy regimen. In March 2025, the FDA expanded that indication to include patients who have received ARPI therapy and for whom chemotherapy can be appropriately delayed. This moved the treatment earlier in the disease sequence for some men.

Insurers rely on FDA approval when deciding whether to cover a treatment. Since Pluvicto went through a large Phase 3 clinical trial and earned full FDA approval, insurers cannot claim it is unproven. However, each insurer sets its own coverage rules, and these do not always match the current FDA label. If your plan's oncology rules were written before the 2025 expansion, they may only cover the older post-chemotherapy indication. Your doctor can fix this by submitting documentation about the current label.

Why Insurers Deny Lu-177 PSMA Claims

Knowing the specific reason for a denial matters because the appeal strategy depends on it. Common reasons include:

  • Not medically necessary: The insurer's reviewer decided your case does not meet their internal coverage criteria, even if it meets the FDA-approved label. This is the most common denial type and most often gets overturned on appeal when you add solid clinical documentation.
  • Step therapy not satisfied: The plan requires proof that you tried and failed certain prior therapies before you receive Pluvicto. If that documentation was missing from the original request, you can usually add it in the appeal.
  • Policy lag: The insurer has not yet updated its oncology coverage policy to reflect the FDA's 2025 expanded indication. A letter from your oncologist citing the current label can address this directly.
  • Missing prior authorization: You received treatment without pre-approved authorization. This is one of the hardest denial types to reverse because you missed the authorization step before care started.
  • Billing or diagnosis code mismatch: A mismatch between the codes submitted and the insurer's covered indication. This is usually an administrative fix - a corrected resubmission resolves it.

If you got a formal denial and are unsure whether it was based on eligibility criteria or on administrative issues, the article on understanding a Lu-177 PSMA denial and getting a second opinion explains how to read and understand your denial letter.

How to Appeal a Denial

Under the Affordable Care Act, you have the right to appeal most insurance claim denials. The American Cancer Society outlines two levels of appeal: an internal review with your insurer and an external review by an independent third party if the internal appeal fails. Work through them in order.

  1. Get the denial in writing and read it carefully. Request your Explanation of Benefits (EOB) and look for the exact denial code and reason. You must address the exact language used in that document in your appeal.
  2. Involve your oncology team right away. Most comprehensive cancer centers have prior authorization teams or patient financial navigators who handle these appeals regularly. Ask for their help as soon as the denial arrives. They know which language works with reviewers.
  3. Build a letter of medical necessity. Ask your oncologist to write a letter listing the current FDA-approved indication, your PSMA-PET scan findings, your full prior treatment history, and the published clinical evidence. The VISION trial, published in the New England Journal of Medicine, showed that lutetium Lu 177 vipivotide tetraxetan reduced the risk of death by 38% and significantly delayed radiographic disease progression compared to standard of care alone in mCRPC patients. Including peer-reviewed evidence in your appeal letter helps reviewers make the right decision.
  4. Request a peer-to-peer review. This is a direct phone call between your oncologist and the insurance company's medical director. Your doctor makes the clinical case in real time and can challenge the reviewer's reasoning directly. This step overturns many denials that survive a written appeal.
  5. File an external review if the insurer denies your internal appeal. An independent organization - not your insurer - reviews the case. Federal law gives you this right for most non-grandfathered health plans. Your state insurance commissioner's office can direct you to the correct process. You must file quickly, as deadlines for external review are short.

Keep a written log of every step: the date of each submission, the name of every person you spoke with, call reference numbers, and copies of all documents sent and received. Many plans set appeal deadlines between 30 and 180 days from the original denial notice.

Medicare Coverage for Lu-177 PSMA Therapy

Pluvicto is typically billed under Medicare Part B, which covers physician-administered drugs. Part B may cover it when you meet FDA-approved eligibility criteria and receive treatment at a Medicare-participating facility. Your standard Part B cost-sharing is 20% of the Medicare-allowed amount after the annual deductible. A Medigap (Medicare Supplement) policy can significantly reduce or eliminate that out-of-pocket share.

If you are enrolled in a Medicare Advantage (Part C) plan, coverage generally follows traditional Medicare rules - but your plan may add its own prior authorization requirements. Some Medicare Advantage plans have faced criticism for denying treatments that traditional Medicare would cover. If your Medicare Advantage plan denies a Pluvicto request, you follow the same internal-then-external appeal process.

One important note: the Novartis co-pay assistance program for Pluvicto is not available to Medicare or Medicaid beneficiaries. If you are on Medicare and still face high out-of-pocket costs after coverage is confirmed, ask your oncology social worker about nonprofit assistance programs - such as those run by the Patient Advocate Foundation or the HealthWell Foundation - that can help pay for remaining costs.

Novartis Financial Assistance for Pluvicto

For patients with commercial (private) insurance, Novartis offers a co-pay support program that may help reduce out-of-pocket costs up to a set limit over the course of treatment. Contact the Novartis patient support line at 1-844-638-7222 to check whether you qualify and how to apply.

For patients who are uninsured or underinsured and cannot afford the medication, the Novartis Patient Assistance Foundation may give you Pluvicto free if you qualify. The foundation can be reached at 1-800-277-2254. Your oncology social worker or financial counselor will help you apply and know what documentation you need. If your center does not have a dedicated financial navigation team, ask for a referral to a social worker before your first cycle - not after.

When Insurance Falls Short: The Treatment-Abroad Path

Some patients - particularly those outside the United States or those whose appeals have not succeeded - consider getting Lu-177 PSMA therapy at established nuclear medicine centers in India, where you pay much less out of pocket. For patients from the GCC region, Africa, South Asia, or other parts of the world where Pluvicto is not available or is too expensive, this path gives you access without insurance delays. A detailed breakdown of what patients actually pay in each market is in our article on Lu-177 PSMA therapy cost in India vs the US.

Before you commit to travel or self-pay costs, get a clear answer on whether you actually qualify for the treatment - and what happens if you do not. You can get your eligibility reviewed through Art of Healing Cancer, which handles eligibility reviews and teleconsultations for international patients. If Lu-177 doesn't fit your scan results and pathology, they can suggest other options.

If you want independent clinical documentation to support a US insurance appeal - or simply a fresh specialist perspective on your eligibility - our guide on getting a second opinion on Lu-177 PSMA eligibility explains what to prepare and how the expert review works.

Confirm Prior Authorization Before Your First Cycle

Almost every US insurer requires prior authorization before you get Pluvicto. Confirm in writing - by email or through your patient portal message - that your authorization is approved, which cycles it covers, and what your expected cost-sharing will be for each one. Do this before you schedule your first infusion, not after. Missing prior authorization after care starts is much harder to fix than getting approval first. If you're not sure your care team submitted the request, call the billing department directly and ask. Get a reference number.

When to Talk to Your Doctor

Talk to your oncology team before your first cycle if you have any uncertainty about your coverage status. Ask specifically: has prior authorization been submitted and confirmed? What is the plan if it is denied? Is there a financial navigator or oncology social worker at this center who can help with appeals? If you receive a denial letter after treatment has started, contact your doctor's office the same day. Appeal windows close quickly, and missing a deadline ends your right to appeal.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does Medicare cover Pluvicto (Lu-177 PSMA therapy)?

Medicare Part B may cover Pluvicto for eligible patients who meet the FDA-approved criteria and receive treatment at a Medicare-participating facility. Standard Part B cost-sharing applies - usually 20% of the Medicare-allowed amount after the deductible. A Medigap policy can reduce or eliminate that coinsurance. The Novartis co-pay assistance program is not available for Medicare beneficiaries; ask your oncology social worker about nonprofit assistance programs such as the Patient Advocate Foundation or HealthWell Foundation for help with remaining out-of-pocket costs.

What should I do if my insurance denies Lu-177 PSMA therapy?

Request the denial in writing and identify the exact reason. Then ask your oncology team to file an internal appeal with a letter of medical necessity that references your PSMA-PET results, your treatment history, and the clinical evidence from the VISION trial. If the internal appeal does not succeed, request a peer-to-peer review - a direct call between your oncologist and the insurer's medical director. If that also fails, file an external review with an independent organization. Keep a log of every submission and deadline throughout the process.

What is a peer-to-peer review and does it help with Lu-177 denials?

A peer-to-peer review is a direct phone call between your oncologist and the insurance company's medical director. Your doctor presents your clinical case in real time and can challenge the reviewer's reasoning directly. This step is often the single most effective way to reverse a denial that has survived an initial written appeal, because a trained specialist can address the reviewer's specific concerns in a way that written documentation alone sometimes cannot.

Does Novartis have a financial assistance program for Pluvicto?

Yes. For commercially insured patients facing high out-of-pocket costs, Novartis offers a co-pay support program. Contact the patient support line at 1-844-638-7222 to check eligibility. For uninsured or underinsured patients who cannot afford the medication, the Novartis Patient Assistance Foundation may provide Pluvicto at no cost to eligible patients - call 1-800-277-2254. Neither program is available to Medicare or Medicaid beneficiaries. Your oncology social worker can help you apply.

Can I still access Lu-177 PSMA therapy if my insurance keeps denying coverage?

If all domestic appeals are exhausted, some patients explore self-pay treatment at experienced nuclear medicine centers in India, where the treatment is available at a significantly lower cost than US list prices and does not involve the same insurance authorization process. A teleconsultation with a specialist team can help you understand whether this path is appropriate for your specific situation and whether you meet the eligibility criteria for treatment.

Why does the VISION trial matter for an insurance appeal?

The VISION trial was the pivotal Phase 3 study that led to the FDA approval of Pluvicto. Published in the New England Journal of Medicine, it showed that lutetium Lu 177 vipivotide tetraxetan was associated with a 38% reduction in the risk of death and a significant delay in radiographic disease progression compared to standard of care alone in mCRPC patients. Citing this trial in a letter of medical necessity helps demonstrate to an insurer's medical reviewer that the treatment is evidence-based and supported by high-quality clinical data - not experimental or investigational.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA Insurance Coverage and Appeals Guide | lutetium-therapy